Reporter brief
Metformin RCT for slowing geographic atrophy progression in age-related macular degeneration
What happened
This RCT tested whether metformin, an FDA-approved diabetes drug, could slow geographic atrophy progression in non-diabetic patients with age-related macular degeneration. The abstract does not report sample size, baseline characteristics, duration, outcomes, or results.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Non-diabetic patients with Age-related Macular Degeneration (AMD)
- Design
- Rct
- Sample
- —
- Journal
- University of California, San Francisco
- Published
- Jun 9, 2023
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Metformin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.